OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy

FR104 shows immune tolerance superiority over CTLA4-Ig in humanized skin transplant model; FR104 efficacious in graft-versus-host reaction in bone marrow transplant model…